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kinase immunohistochemistry (ALK 
IHC) systems. I agree with their conclu-
sion that IHC is reliable for detection of 
ALK rearrangement; however, I would 
like to comment on their interpretation 
of individual results.
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They determined the sensitivity 
and specificity of five systems includ-
ing “any ALK expression by IHC on 
tissue microarray (TMA) or whole 
section (WS),” using fluorescent in 
situ hybridization (FISH) on WS as 
the standard.1 According to their crite-
ria, both sensitivity and specificity of 
ALK1-ADVANCE should be 100%; 
however, these values are stated as 66% 
and 87.5%, respectively, in Table 3.1
A TMA specimen corresponds 
to a part of the WS. Therefore, if a 
TMA scores 2+, the corresponding 
WS should score 2+ focal (hetero-
geneity) or higher. If a WS scores 
2+ diffuse, the corresponding TMA 
always scores 2+. Interestingly, for the 
5A4-Histofine staining in cases 10 and 
11, the TMA and WS results are dif-
ferent by two scores (2+ or 0) (Tables 
1 and 2).1 This score difference might 
be because of either serious staining 
errors, or accidental interchanging of 
the results because such high differ-
ence is unlikely unless heterogeneity 
exists in the WS, and actually, het-
erogeneity was not observed in the 
WS. Similarly, the score difference of 
ALK1-ADVANCE for case 3 is also 
unlikely. Therefore, I would like the 
authors to check these results and re-
stain the sections.
For ALK1 staining, the TMA 
and WS scores show discordance (1+ 
or 0) for cases 3 and 11. Such discor-
dance may occur because the observer 
struggled to determine whether the 
faint positivity of score 1+ was real 
positivity, unlike the readily detect-
able staining of score 2+ and 3+, as 
mentioned by the authors.1 Given that, 
would it be appropriate to define score 
1+ as positive while calculating sensi-
tivity? From this point of view, in case 
11, the best and practical sensitivity 
was obtained only with 5A4-Histofine 
staining—a readily detectable staining 
of score 2+—whereas with other stains, 
the scores were either 1+ or 0 (Table 2).1
In my published2,3 and unpub-
lished records for anti-ALK IHC of more 
than 4500 lung cancer cases by using the 
intercalated antibody-enhanced poly-
mer (iAEP) method,3 a highly-sensitive 
method on which the 5A4-Histofine 
staining is based, almost all cancer cells 
were stained in more than 300 ALK-
rearranged cases. This staining homo-
geneity supports the view that all tumor 
cells of ALK-rearranged tumors harbor 
ALK rearrangement.4 Wild-type ALK 
is weakly expressed physiologically in 
normal nerve cells.5 Therefore, lung 
cancers without ALK rearrangement 
sometimes show positivity in highly 
sensitive anti-ALK IHC, such as the 
iAEP method, especially in cases with 
neuroendocrine differentiation (small-
cell, large-cell neuroendocrine, and 
other carcinomas with focally neuro-
endocrine differentiation).2 However, 
unlike in ALK-rearranged cases, the 
staining pattern in these cases is usu-
ally heterogeneous probably because 
the physiological expression status var-
ies from cell to cell (Fig. 1). In highly 
sensitive anti-ALK IHC for detection 
of ALK rearrangement, therefore, a het-
erogeneous staining pattern should not 
be interpreted as positive for ALK rear-
rangement, but should be considered 
probably negative for ALK rearrange-
ment, and then be confirmed through 
FISH. This anti-ALK IHC interpreta-
tion would have made the specificities 
of 5A4-ADVANCE and 5A4-Histofine 
100% (Table 2).1
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